Third-generation EGFR-TKI becoming a R&D hotspot
Sales of Osimertinib Approaching RMB 2 Billion in China in 2018
BPI-7711 of Beta Pharma into Phase III Clinical Trial.
Third-generation EGFR-TKI becoming a R&D hotspot
Sales of Osimertinib Approaching RMB 2 Billion in China in 2018
BPI-7711 of Beta Pharma into Phase III Clinical Trial.